AI Article Synopsis
- The occurrence of adverse reactions to cromolyn sodium in asthmatic patients was low, at 2%, and included dermatitis, myositis, and gastroenteritis.
- The reactions were non-life-threatening and fully reversible, indicating they were not serious.
- Immunological tests showed no signs of an immune response, suggesting that adverse reactions are not due to an immunologic mechanism, confirming cromolyn's safety as an asthma treatment.
Article Abstract
The frequency of adverse reactions (dermatitis, myositis, and gastroenteritis) to cromolyn sodium in asthmatic patients was 2% (B/375). Reactions were non-life-threatening and completely reversible. Immunologic evaluations, including skin and serum tests for immediate and delayed reactivity, all were negative. Adverse reactions to cromolyn do not appear to be based on an immunologic mechanism. Cromolyn appears to be a safe drug for the treatment of asthma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.
Blood
January 2025
Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.
View Article and Find Full Text PDFImmune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System.
Age Ageing
January 2025
Department of Medical Oncology, Koç University Hospital, Davutpaşa Street 34010 Topkapı, Istanbul, Turkey.
Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet they carry a unique spectrum of immune-related adverse events (irAEs). Given the ageing global population and the underrepresentation of older adults in clinical trials for ICIs, we investigated the occurrence and characteristics of irAEs in older versus younger adults as well as among different age subsets within the older adult population.
Methods: We analysed the U.
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Liposomal amphotericin B and complement activation-related pseudoallergy (CARPA).
Antimicrob Agents Chemother
January 2025
Department of Medical Microbiology and Immunology, University of California-Davis, Davis, California, USA.
Infusion reactions (tachycardia, hypertension, fever, etc.) associated with liposomal amphotericin B are common. Animal models have found complement activation responsible, yet the pathophysiology has not been evaluated in human patients.
View Article and Find Full Text PDFA study on the pharmacovigilance of various SGLT-2 inhibitors.
Front Med (Lausanne)
January 2025
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Sodium-glucose co-transporter two inhibitors (SGLT2is) are widely used in clinical practice due to their proven cardiovascular and renal benefits. However, various adverse drug reactions (ADRs) have been reported. This study aims to systematically update the ADRs associated with SGLT2is and identify the differences among various SGLT2is acovigilance of various SGLT-2 inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!